Infected pancreatic necrosis (IPN), carries a 20-40% mortality risk despite current surgical therapies 1–3. Although minimally invasive active debridement techniques exist – aggressive pancreatic lavage, snares, and Dorima basket fragmentation – up to 50% of patients eventually require surgical necrosectomy due to incomplete removal of infected tissue 4. The aim of this retrospective study was to evaluate outcomes in patients who received a new, augmented form of active pancreatic necrosectomy with the Argon CleanerXT Thrombectomy Device. The study included individuals from 2015-2017 diagnosed with IPN who received augmented active pancreatic necrosectomy secondary to failure of passive percutaneous drainage (n = 6). Major study endpoints included patient mortality and need for subsequent surgical necrosectomy. An Unpaired t-test and Mann Whitney test were used to compare the outcomes in patients treated with augmented necrosectomy versus previously reported outcomes in patients treated with traditional active pancreatic necrosectomy (n = 18) 4. A P value of No patients died of IPN when treated with augmented pancreatic necrosectomy compared to an IPN related mortality rate of approximately 20% in patients treated with traditional active pancreatic necrosectomy (P = 0.22-0.23) 4. No patients required surgical necrosectomy compared to a subsequent surgical necrosectomy rate of approximately 55% reported in the literature (P = 0.016-0.021). Augmentation with the Argon CleanerXT led to complete recovery and no need for subsequent surgery in all patients. The decreased need for surgery may be related to improved debridement as the Argon CleanerXT is optimized for mechanical fragmentation. Differences in mortality were not found to be statistically significant; however, decreased need for surgical intervention was statistically significant. Given the known positive relationship between surgical intervention and mortality, the lack of statistical significance is likely related to sample size. Larger studies controlling for differences in patient variables are now needed to validate this new treatment modality for IPN.